Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the years, but the range of approved drugs has expanded. Semaglutide and tirzepatide are the most commonly used today. Primary care providers play an important role in the individualized medical management of overweight patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- From biomarkers to gene therapies
Getting to know ataxias
- Evidence-based therapy for psoriasis in difficult locations
IL-23 inhibition in scalp psoriasis: what’s new?
- Obesity in the family practice
Aim for realistic goals and avoid apportioning blame
- Evidence, pathophysiology and management in the light of current data
Heart failure with improved ejection fraction (HFimpEF)
- Early rheumatoid arthritis
C1M has potential as a biomarker
- Osteoporosis
Risk-stratified therapy with osteoanabolic agents improves outcomes
- "Swiss Health Care Atlas"
New indicator: medication for weight regulation
- AI in neurology